Comparative Pharmacology
Head-to-head clinical analysis: KAINAIR versus MAXAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAINAIR versus MAXAIR.
KAINAIR vs MAXAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
25 mg subcutaneously three times daily.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
None Documented
None Documented
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 mL/min).
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Category C
Category C
Bronchodilator
Bronchodilator